Please assess the completion status of the following clinical trial:

Trial Title: Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients \< 65 years with hematologic malignancies needing stem cell transplant but do not have HLA-matched sibling donor. Patients with the following diagnosis will be included:~  * AML in first or subsequent complete or partial remissions~ * ALL in first or subsequent complete or partial remissions~ * CLL in second remission or more advanced disease~ * CML who has failed tyrosine kinase inhibitors~ * Hodgkin's disease who relapse after autologous transplant~ * Non-Hodgkin's lymphoma who relapse after autologous transplant or NK-cell lymphoma in CR1~ * Aplastic anemia patients~ * Multiple myeloma in second remission or moer advanced disease, including those who have failed an autologous transplant~ * Myelodysplastic syndrome in first or subsequent complete or partial remission~* Patients must have 6/6, 5/6 or 4/6 molecular matches from unrelated UCB donors. Matching will be done for A, B, and DR. Matching at DR will be confirmed by molecular typing.~* Patients must be documented to be HIV negative. Screening must have been performed within previous 6 months.~* Patients must be able to give written consent.~Exclusion Criteria:~* Patient is excluded if all of the Inclusion criteria above isn't met.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Single Arm (Type: EXPERIMENTAL): The following conditioning regimens will be used, depending on the underlying hematologic malignancies. Conditioning regimens with Busulfan/clofarabine and with fludarabine/melphalan will be used for all patients except those with Non-Hodgkin's lymphoma when the conditioning regimen of BCNU, Etoposide, ARA-C and Melphalan will be used.

Based on this trial design, predict the completion outcome and termination type (if applicable).